Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
- decodeMR Team
- 4 hours ago
- 1 min read
12/02/2026
The European Commission approved inebilizumab for the treatment of generalized myasthenia gravis (Ref)
The European Commission approved Amgen’s Uplizna®(inebilizumab; anti-CD19 mAb) as an add-on treatment to standard therapy for adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (MuSK) antibody positive
The approval was based on data from the Phase 3, MINT/ NCT04524273 study
This was the first and only CD19-targeted therapy approved in the EU for adults with anti-AChR+ and anti-MuSK+ gMG
UPLIZNA demonstrated durable disease control with twice-yearly dosing
